AngioBiomed Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 2

AngioBiomed General Information

Description

Developer of patent-protected mouse monoclonal antibodies intended for cancer patients. The company's drug blocks the interaction between the vasoactive peptide hormone adrenomedullin and its receptor, so that the formation of new blood vessels stagnates, enabling patients to be treated for cancer by significantly reducing tumor progression.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Neuendorfstr. 15 b
  • 16761 Hennigsdorf
  • Germany
Primary Industry
Drug Discovery
Vertical(s)
Corporate Office
  • Neuendorfstr. 15 b
  • 16761 Hennigsdorf
  • Germany

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AngioBiomed Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore AngioBiomed‘s full profile, request access.

Request a free trial

AngioBiomed Patents

AngioBiomed Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
ES-2865303-T3 Adrenomedullin binder for use in cancer therapy Active 20-Dec-2013
EP-3082858-A1 Adrenomedullin binder for use in therapy of cancer Active 20-Dec-2013
EP-3082858-B1 Adrenomedullin binder for use in therapy of cancer Inactive 20-Dec-2013 A61K39/395

AngioBiomed Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore AngioBiomed‘s full profile, request access.

Request a free trial

AngioBiomed FAQs

  • When was AngioBiomed founded?

    AngioBiomed was founded in 2015.

  • Where is AngioBiomed headquartered?

    AngioBiomed is headquartered in Hennigsdorf, Germany.

  • What industry is AngioBiomed in?

    AngioBiomed’s primary industry is Drug Discovery.

  • Is AngioBiomed a private or public company?

    AngioBiomed is a Private company.

  • What is AngioBiomed’s current revenue?

    The current revenue for AngioBiomed is .

  • Who are AngioBiomed’s investors?

    Deutsche Biotech Innovativ has invested in AngioBiomed.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process